Litigation Details for ViiV Healthcare Company v. Gilead Sciences, Inc. (D. Del. 2018)
✉ Email this page to a colleague
ViiV Healthcare Company v. Gilead Sciences, Inc. (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-02-06 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | Plaintiff | Referred To | Christopher J. Burke |
| Parties | VIIV HEALTHCARE COMPANY | ||
| Patents | 10,092,009; 10,184,001; 6,011,049; 7,015,018; 7,262,019; 8,008,003; 8,022,095; 8,044,014; 8,048,017; 8,063,015; 8,129,385; 9,000,002; 9,006,224; 9,010,165; 9,022,022; 9,127,013; 9,216,996; 9,297,018 | ||
| Attorneys | John M. Hughes | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ViiV Healthcare Company v. Gilead Sciences, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in ViiV Healthcare Company v. Gilead Sciences, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for ViiV Healthcare Company v. Gilead Sciences, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-12-22 | 162 | Redacted Document | x27; 44:7, 63:13 44:2, 44:8, 44:14, modify[1J- 40…that the Patent Office did not really consider the patent-in-suit when granting Gilead’s patent for …its own patent over the ’385 patent. These conclusions would apply equally to the patent- in-suit…the ’385 Patent and Gilead’s Patent Does Not Bear on Whether the Two Patents Include…applied to the patent-in-suit (U.S Patent No. 8,129,385, the “’385 patent”) and related applications | External link to document |
| 2020-02-04 | 174 | Opinion - Memorandum Opinion | infringing United States Patent Number 8,129,385 (the #385 patent). The #385 patent covers pharmaceutical…principle of patent law that the claims of a 2 patent define the…requirements for a patent.") ( citation omitted). It is the claims-not the patent's written description…Bictegravir infringes claims 2 and 6 of the #3 85 patent under the doctrine of equivalents. That doctrine… literally infringe upon the express terms of a patent claim may nonetheless be found to infringe if | External link to document |
| 2020-02-09 | 176 | Notice of Service | Dobkin, M.D. Regarding Infringement of U.S. Patent No. 8,129,385; (3) Reply Expert Report of Jennifer Dressman…Guengerich, Ph.D., Regarding Infringement of U.S. Patent No. 8,129,385; (6) Reply Expert Report of Kenneth M. Merz…Gilead Sciences, Inc.s Infringement of U.S. Patent No. 8,129,385; (7) Supplemental Reply Expert Report of…Gilead Sciences, Inc.s Infringement of U.S. Patent No. 8,129,385; (8) Expert Report of Timothy Simcoe, Ph.D…Gilead Sciences, Inc.s Infringement of U.S. Patent No. 8,129,385 filed by Shionogi & Co., Ltd., ViiV Healthcare | External link to document |
| 2020-04-21 | 235 | Redacted Document | claimed embodiment of claims 2 and 6 of U.S. Patent 8,129,385) and bictegravir (“BIC) sodium (“BIC sodium…claimed embodiment of claims 2 and 6 of U.S. Patent 8,129,385) and bictegravir (“BIC”) are insubstantial…INC.’S INFRINGEMENT OF U.S. PATENT NO. 8,129,385 …Gilead Sciences, Inc.’s Infringement of U.S. Patent No. 8,129,385 (“Merz Opening Report”), the February …Gilead Sciences, Inc.’s Infringement of U.S. Patent No. 8,129,385 (“Merz Reply Report”), and the February | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
